← 返回

激素受体/HER2+ 早期乳腺癌的肿瘤免疫微环境与新辅助化疗反应

英文原题:Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.

查看英文原题

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.

PubMed 2022/04/18(内容时间) Clin Breast Cancer Q3 · IF 2.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TME 特征分析显示,HER2 阳性乳腺癌患者中若干基质 T 细胞密度和免疫细胞聚集与 pCR 相关。这些结果证明了这些新方法在 TME 评估中的可行性,并为正在进行的 HER2+早期乳腺癌 TME 研究做出贡献,以识别可靠的生物标志物,从而最佳地识别适合全身降阶梯策略的患者。

研究思路结论见上方概要

HER2阳性早期乳腺癌新辅助治疗后的手术时病理反应影响预后和后续辅助治疗。HER2阳性早期乳腺癌患者肿瘤微环境(TME)的全面描述尚不充分。我们利用标准间质病理学家评估的TIL(肿瘤浸润淋巴细胞)定量、定量多重免疫荧光和基于RNA的基因通路特征,评估了在激素受体阳性、HER2阳性早期乳腺癌患者中新辅助治疗前TME特征与病理完全缓解的相关性。

我们利用标准的基质病理学家评估的 TIL 定量、多重免疫荧光定量以及基于 RNA 的基因通路特征,评估了 28 例接受新辅助治疗激素受体阳性、HER2 阳性早期乳腺癌患者中,治疗前 TME 特征与病理完全缓解的相关性。

病理学家评估的间质 TIL 与病理完全缓解(pCR)显著相关。通过定量多重免疫荧光,单因素分析显示 pCR 患者中 CD3+、CD3+CD8-FOXP3-、CD8+ 和 FOXP3+ T 细胞密度显著增加,免疫细胞聚集也增多。在配对治疗前/后样本的子集中,我们观察到非 pCR 患者的基因表达特征发生显著变化,而 pCR 患者治疗后 CD8+ 密度显著降低。未发现基于 RNA 的通路特征与 pCR 相关。

展开英文摘要原文

Pathologic response at the time of surgery after neoadjuvant therapy for HER2 positive early breast cancer impacts both prognosis and subsequent adjuvant therapy. Comprehensive descriptions of the tumor microenvironment (TME) in patients with HER2 positive early breast cancer is not well described. We utilized standard stromal pathologist-assessed tumor infiltrating lymphocyte (TIL) quantification, quantitative multiplex immunofluorescence, and RNA-based gene pathway signatures to assess pretreatment TME characteristics associated pathologic complete response in patients with hormone receptor positive, HER2 positive early breast cancer treated in the neoadjuvant setting.

We utilized standard stromal pathologist-assessed TIL quantification, quantitative multiplex immunofluorescence, and RNA-based gene pathway signatures to assess pretreatment TME characteristics associated pathologic complete response in 28 patients with hormone receptor positive, HER2 positive early breast cancer treated in the neoadjuvant setting.

Pathologist-assessed stromal TILs were significantly associated with pathologic complete response (pCR). By quantitative multiplex immunofluorescence, univariate analysis revealed significant increases in CD3+, CD3+CD8-FOXP3-, CD8+ and FOXP3+ T-cell densities as well as increased immune cell aggregates in pCR patients. In subsets of paired pre/post-treatment samples, we observed significant changes in gene expression signatures in non-pCR patients and significant decreases in CD8+ densities after treatment in pCR patients. No RNA based pathway signature was associated with pCR.

TME characterization HER2 positive breast cancer patients revealed several stromal T-cell densities and immune cell aggregates associated with pCR. These results demonstrate the feasibility of these novel methods in TME evaluation and contribute to ongoing investigations of the TME in HER2+ early breast cancer to identify robust biomarkers to best identify patients eligible for systemic de-escalation strategies.

论文信息

作者
Vanguri RS、Fenn KM、Kearney MR、Wang Q、Guo H、Marks DK、Chin C、Alcus CF
第一作者单位
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.United States
通讯作者单位
Division of Radiation Oncology, Columbia University Irving Medical Center, New York, NY. Electronic address: epc2116@cumc.columbia.edu.United States
文献类型
美国 NIH 资助研究
期刊
Clinical breast cancer2022 Aug
原文标识
PubMed 35610143 · DOI 10.1016/j.clbc.2022.04.002